---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-021159"
form_type: "8-K"
ticker: "BGMS"
cik: "0001130166"
company_name: "Bio Green Med Solution, Inc."
filed_at: "2025-07-28T23:59:59+00:00"
generated_at: "2026-05-18T00:07:38.311740+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cyclacel removes ownership limitation on Series F Convertible Preferred Stock

## Summary
- Filed Amended Certificate of Designation removing Series F Ownership Limitation that capped conversion/voting at 4.99% of common stock.
- Effective July 28, 2025, after board and majority stockholder approval per Schedule 14C filed July 7, 2025.
- No other changes to Series F Convertible Preferred terms; removal allows unrestricted conversion and voting.
- Potential for increased dilution if holders convert shares without prior ownership cap.

## SEC filing metadata
- accession: 0001641172-25-021159
- form_type: 8-K
- ticker: BGMS
- cik: 0001130166
- company_name: Bio Green Med Solution, Inc.
- filed_at: 2025-07-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130166/000164117225021159/0001641172-25-021159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130166/000164117225021159/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-021159
- JSON: https://secwatch.observer/filing/0001641172-25-021159.json
- Plain text: https://secwatch.observer/filing/0001641172-25-021159.txt

## Key facts
- Governance Changes
  Bio Green Med Solution, Inc.: Filing of Amended and Restated Certificate of Designations for Series F Convertible Preferred Stock removing the Series F Ownership Limitation (effective 2025-07-28).
  - Change: charter amendment
  - Effective: 2025-07-28
  source text: On July 28, 2025, after obtaining the approval of the Board of Directors and majority stockholder of Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the “Company”) as disclosed in the Company’s Definitive Information Statement on Schedule 14C filed with the Securities and Exchange Commission on July 7, 2025 (the “Schedule 14C”), the Company filed an Amended and Restated Certificate of Designations, Preferences, Rights and Limitations of Series F Convertible Preferred Stock (the “Restated Certificate of Designation”) with the Secretary of State of the State of Delaware.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130166/000164117225021159/0001641172-25-021159-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.